Generative artificial intelligence (GenAI) is becoming a part of our lives, personally and professionally. Much of the current discourse focuses on its capabilities and ethical risk, while some ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Abstract: In this research paper, we present a novel method for obtaining the patterns of inputs that generate low-weight codewords in Recursive Systematic Convolutional (RSC) codes, hereafter ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Kurt Gödel approached the divine from two angles: his incompleteness theorems showed that formal systems can’t be both complete and consistent, while his ontological argument used modal logic to prove ...

SAN ANTONIO, TX, UNITED STATES, July 10, 2025 /EINPresswire.com/ -- Independent AI researcher Mark McLemore today published groundbreaking findings demonstrating that ...